Form 4 for RVMD Revolution Medicines, Inc.
Accepted 2026-06-26 16:10:03 ET · period of report 2026-06-24 · accession 0001610717-26-000296 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-06-26 16:10 | 2026-06-24 | RVMD | Anders Jack | CFO | M - OptEx | $18.56 | +20.0K | 143.3K | +16% | +$371.2K |
| DMT | 2026-06-26 16:10 | 2026-06-24 | RVMD | Anders Jack | CFO | S - Sale+OE | $168.33 | -20.0K | 123.3K | -14% | -$3.37M |
| DT | 2026-06-26 16:10 | 2026-06-24 | RVMD | Anders Jack | CFO | M - OptEx | $0.00 | +20.0K | 20.6K | +3,333% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-24 | M | A | 20,000 | $18.56 | 143,269 | D | — | — | (F1) Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 24, 2026. (F2) Includes 51,388 restricted stock units. |
| 2 | Common | Common Stock | 2026-06-24 | S | D | 4,553 | $167.34 | 138,716 | D | — | — | (F1) Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 24, 2026. (F3) This transaction was executed in multiple trades at prices ranging from $166.76 to $167.75. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. (F2) Includes 51,388 restricted stock units. |
| 3 | Common | Common Stock | 2026-06-24 | S | D | 9,496 | $168.20 | 129,220 | D | — | — | (F1) Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 24, 2026. (F4) This transaction was executed in multiple trades at prices ranging from $167.77 to $168.75. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. (F2) Includes 51,388 restricted stock units. |
| 4 | Common | Common Stock | 2026-06-24 | S | D | 5,651 | $169.24 | 123,569 | D | — | — | (F1) Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 24, 2026. (F5) This transaction was executed in multiple trades at prices ranging from $168.78 to $169.74. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. (F2) Includes 51,388 restricted stock units. |
| 5 | Common | Common Stock | 2026-06-24 | S | D | 300 | $170.32 | 123,269 | D | — | — | (F1) Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 24, 2026. (F6) This transaction was executed in multiple trades at prices ranging from $169.81 to $170.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. (F2) Includes 51,388 restricted stock units. |
| 6 | Derivative | Stock Option (Right to Buy) | 2026-06-24 | M | A | 20,000 | $0.00 | 20,600 | D | $18.56 · 2026-03-01 to 2032-02-29 | 20,000 Common Stock | (F1) Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 24, 2026. |